# Drug-Drug Interaction Between PK101-001 and PK101-002

> **NCT03553316** · PHASE1 · COMPLETED · sponsor: **PMG Pharm Co., Ltd** · enrollment: 49 (actual)

## Conditions studied

- Arthritis

## Interventions

- **DRUG:** PK101-002
- **COMBINATION_PRODUCT:** PK101

## Key facts

- **NCT ID:** NCT03553316
- **Lead sponsor:** PMG Pharm Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2019-03-22
- **Final completion:** 2019-04-24
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03553316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03553316, "Drug-Drug Interaction Between PK101-001 and PK101-002". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03553316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*